Breaking Finance News

A statement released earlier today by Credit Suisse about AstraZeneca PLC (LON:AZN) maintains the target price at 4,000.00GBX

Credit Suisse hold steady the target of AstraZeneca PLC (LON:AZN) at 4,000.00GBX stating a potential downside of -0.20%.

On 10/05/2016, Citigroup released a statement on AstraZeneca PLC (LON:AZN) maintained the target price at 6,000.00GBX that suggested an upside of 0.20%.

Boasting a price of 5,030.00GBX, AstraZeneca PLC (LON:AZN) traded 1.19% higher on the day. With the last close up 14.66% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. AstraZeneca PLC has recorded a 50-day average of 5,005.11GBX and a two hundred day average of 4,435.88GBX. Volume of trade was up over the average, with 3,384,720 shares of AZN changing hands over the typical 2,645,380

Performance Chart

AstraZeneca PLC (LON:AZN)

With a total market value of 0 GBX, AstraZeneca PLC has price-earnings ratio of 29.06 with a one year low of 3,680.00GBX and a one year high of 5,505.00GBX .

A total of 29 analysts have released a research note on AZN. Four analysts rating the company a strong buy, fourteen analysts rating the company a buy, thirteen analysts rating the company a hold, two analysts rating the company a underperform, and finally one analyst rating the company a sell with a one year target of 61.96GBX.

More About AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.